Boston Scientific loses appeal in J&J case
This article was originally published in The Gray Sheet
Executive SummaryCourt of Appeals for the Federal Circuit in Washington, D.C., finds Boston Scientific's "Ding" patent for a drug-eluting stent coating system to be invalid as obvious over prior art. The ruling overturns a 2005 jury verdict in the U.S. District Court of Delaware that found the patent was valid and infringed by Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent (1"The Gray Sheet" June 19, 2006, In Brief). Boston says it is considering options for challenging the decision
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.